SSR411298

DRUG2 trials

Sponsors

Sanofi

Conditions

Breakthrough Cancer PainMajor Depressive DisorderPain

Phase 2

An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients

CompletedNCT00822744

SanofiMajor Depressive Disorder

Start: 2008-12-31End: 2010-02-28Updated: 2013-03-15

A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain

TerminatedNCT01439919

SanofiBreakthrough Cancer Pain, Pain

Start: 2012-01-31End: 2012-02-29Updated: 2013-03-21